Inovio Pharmaceuticals (INO) Stock
DNA vaccine developer targeting infectious diseases and cancer. Here's the price, business snapshot, and what's worth knowing about Inovio Pharmaceuticals in June 2026.
Inovio Pharmaceuticals (INO) is a clinical‑stage biotechnology company developing DNA‑based vaccines and immunotherapies, using a proprietary electroporation delivery platform. Investors should know it is small‑cap and research‑driven: value is tied to clinical trial readouts, regulatory progress and partnerships rather than stable revenues. The company’s pipeline targets infectious diseases and oncology, and progress often comes in discrete, binary milestones that can cause sharp share‑price moves. As a small biopharma, Inovio may need to raise capital from time to time, which can dilute shareholders. Key considerations for investors include the stage and quality of clinical data, cash runway, partner relationships and the competitive landscape for vaccine and immunotherapy technologies. This summary is educational and not personalised advice — biotech investing carries elevated risk and potential volatility, and past developments are not a reliable guide to future results.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Inovio's stock with a target price of $7.63, indicating strong growth potential.
Financial Health
Inovio Pharmaceuticals is struggling to generate significant revenue and cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring INO
Biotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketAntiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Published: 16 November 2025
Explore BasketPediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: 11 July 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: 1 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Pipeline trial readouts and regulatory steps can meaningfully move the share price; however, outcomes are binary and can be volatile.
Platform Innovation
The DNA electroporation approach is central to Inovio’s strategy and may offer differentiation, yet scientific and competitive risk remains.
Funding And Runway
Small‑cap status means funding rounds are possible and can dilute existing holders; monitor cash reports and partnership deals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
